Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis

Journal of the National Cancer Institute

Volumn 98, Issue 7, 2006, Pages 491-498

  Tanaka, Shinji ^a   Pero, Stephanie C ^b   Taguchi, Kenichi ^c   Shimada, Mitsuo ^d   Mori, Masaki ^e   Krag, David N ^b   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; LIGAND; PEPTIDE; PROTEIN INHIBITOR; PROTEIN SH2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; G7 18NATE; G7-18NATE; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CELL MIGRATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; INTRACELLULAR SPACE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TISSUE SECTION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; SRC HOMOLOGY DOMAIN;

ADENOCARCINOMA; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GRB7 ADAPTOR PROTEIN; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PERITONEAL NEOPLASMS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TUMOR CELLS, CULTURED;

EID: 33645735705     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj105     Document Type: Article

References (38)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
4. Pawson T. Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004;116:191-203.
5. Machida K, Mayer BJ. The SH2 domain: Versatile signaling module and pharmaceutical target. Biochim Biophys Acta 2005;1747:1-25.
6. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, et al. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res 1997;57:28-31.
7. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, et al. A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest 1998;102:821-7.
8. Manser J, Roonprapunt C, Margolis B. C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development. Dev Biol 1997;184: 150-64.
9. Akiyama N, Sasaki H, Ishizuka T, Kishi T, Sakamoto H, Onda M, et al. Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. Cancer Res 1997;57:3548-53.
10. Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, Moskow JJ, et al. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 1994;13:1331-40.
11. Margolis B, Silvennoinen O, Comoglio F, Roonprapunt C, Skolnik E, Ullrich A, Schlessinger J. High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains. Proc Natl Acad Sci USA 1992;89:8894-8.
12. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ. Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem 1998;273: 7717-24.
13. Han DC, Shen TL, Guan JL. Role of Grb7 targeting to focal contacts and its phosphorylation by focal adhesion kinase in regulation of cell migration. J Biol Chem 2000;275:28911-7.
14. Feldner JC, Brandt BH. Cancer cell motility - on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272: 93-108.
15. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005;5:505-15.
16. Daly RJ. The Grb7 family of signalling proteins. Cell Signal 1998;10: 613-8.
17. Han DC, Shen TL, Guan JL. The Grb7 family proteins: Structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001;20:6315-21.
18. Pero SC, Daly RJ, Krag DN. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med 2003;5:1-11.
19. Oligino L, Lung FD, Sastry L, Bigelow J, Cao T, Curran M, et al. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J Biol Chem 1997;272:29046-52.
20. Pero SC, Oligino L, Daly RJ, Soden AL, Liu C, Roller PP, et al. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem 2002;277:11918-26.
21. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991;88:1864-8.
22. Tanaka S, Sugimachi K, Kawaguchi H, Saeki H, Ohno S, Wands JR, et al. Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol 2000;183:411-5.
23. Walch A, Specht K, Braselmann H, Stein H, Siewert JR, Hopt U, et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 2004;112:747-53.
24. Scherer LJ, Ross JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003;21:1457-60.
25. Bodanszky M, Bodanszky A, editors. The practice of peptide synthesis. 2nd rev. ed. New York (NY): Springer-Verlag; 1994.
26. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
27. Tanaka S, Wands JR. A carboxy-terminal truncated IRS-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 1996;98:2100-8.
28. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24:496-9.
29. Shakespeare WC. SH2 domain inhibition: A problem solved? Curr Opin Chem Biol 2001;5:409-15.
30. Beeler JF, LaRochelle WJ, Chedid M, Tronick SR, Aaronson SA. Prokaryotic expression cloning of a novel human tyrosine kinase. Mol Cell Biol 1994;14:982-8.
31. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6.
32. Stanger BZ, Stiles B, Lauwers GY, Bardeesy N, Mendoza M, Wang Y, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185-95.
33. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, et al. Etuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
34. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-12.
35. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73.
36. Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I study. Am J Clin Oncol 2005;28:570-5.
37. Shen TL, Han CH, Guan JL. Association of Grb7 with phosphoinositides and its role in the regulation of cell migration. J Biol Chem 2002;277: 29069-77.
38. Jenzora A, Behrendt B, Small JV, Wehland J, Stradal TE. PREL1 provides a link from Ras signalling to the actin cytoskeleton via Ena/VASP proteins. FEBS Lett 2005;579:455-63.